The Company.
CellGenix Technologie Transfer GmbH is an innovative biopharmaceutical company headquartered in Freiburg, Germany. CellGenix, which was founded in 1994 as a spin-off of University Hospital Freiburg, currently has more than 40 employees.

CellGenix develops, manufactures and markets cell and protein therapeutics for tumor and orthopedic patients, as well as high-quality reagents for therapeutic ex vivo cell processing.

The company owns Metreon Bioproducts GmbH, which was founded in 1996 as a joint venture together with Schering AG. CellGenix also owns shares in American Fluoroseal Cooperation (Afc) in Gaithersburg, Maryland (USA), and in CellPrep S.A. in Buenos Aires (Argentina). 
 
Innovative research and development.
CellGenix's research focuses on stem cell therapy for the regeneration of tissues and organs, tumor immunotherapy, and drug targeting, a highly selective cell-specific patient specific therapy, for cancer.

A patient-specific vaccine (IdioVaxR) against lymph node cancer is already in Phase II clinical trial that is being conducted in collaboration with Freiburg's University Hospital and the Center for Clinical Research.

Safety and superior quality.
CellGenix's extensive experience with GMP manufacturing and applications of cell therapeutics has enabled the company to build up a strategically significant portfolio of intangible assets and trade secrets in the field of GMP production of cell and protein therapeutics.

The Ex vivo Therapeutics sector received ISO 9002 certification in late 2000 and received CE certification in June 2002.

Since the Fall 2001, with the expansion of its office and production complex near the Freiburg airport, CellGenix has at its disposal one of the world's most technologically advanced GMP facilities for the processing of individual cell and protein therapeutics.